

### Key information

<i>Database last updated</i>	2021.05.08 13:24:00
Description / title	<b>Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi</b>
Status	Not in force
Legal status	2019.08.11 Ceased
Detailed status	2019.09.03 Patent protection period expired (check also details in the case)
Patent number	332893
Application number	20010699
Filed	2001.02.09
Divided to	20111217;
Priority	1998.08.11, US 96180
Case type	PCT
Registered internationally	1999.08.11
International application number	PCT/US1999/18120
Entry into National Phase	2001.02.09
Effective date	1999.08.11
Expiry date	2019.08.11
Publicly available	2001.04.10
Granted	2017.09.18
Applicant	Biogen Idec Inc (US)
Owner	Biogen Inc. (US)
Inventor	Antonio Grillo-López (US)
Agent	OSLO PATENTKONTOR AS (NO)
Patent family	Look up in Espacenet

## Abstract and drawing

 Patent Translation picture

Nye kombinerte terapeutiske regimer for behandling av B- celle-lymfomer er beskrevet og som omfatter spesielt administrasjon av anti-CD20-antistoff til pasienter som har lav-, mellomliggende- eller høygrads non-Hodgkins lymfom.

[View the abstract and front page figure in Espacenet](#)

## Classes

### IPC class

**A61K 39/395**

A61P 35/00

### CPC class

**A61K 39/39558**

## Applicant(s)

Biogen Idec Inc  
5200 Research Place  
CA92122 SAN DIEGO  
US

## Owner

Biogen Inc.  
225 Binney Street  
MA02142 CAMBRIDGE  
US

---

[History](#)

## Inventor

Antonio Grillo-López  
Alexandria, VA  
US

## Agent

Agent in Norway:

OSLO PATENTKONTOR AS  
Hoffsveien 1A  
0275 OSLO  
NO ( OSLO *Municipality*, OSLO *county* )

Org. number: 910476068

Your reference: 144046 TG/eah

## Priority

1998.08.11, US 96180

## Citations (cited documents)

US 5736137 A (A)

MALONEY, D.G. et al, IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed Non-Hodgkin's lymphoma. *Jour. of Clinic. Oncol.*, 1997.10, Vol. 15, No. 10, s. 3266-74 ()

MCLAUGHLIN, P. et al, Rituximab chimeric anti-CD20 monoklonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. 1998.08, Vol. 16, No. 8, s. 2825-33 ()

VAN DER KOLK, L.E. et al., Chimeric anti-CD20 monoklonal antibody (Rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial, 1998.07.01, *Brit. Jour. of haematol.*, Vol. 102, No. 1, sammendrag ()

US 5736137 A (A)

MALONEY, D.G. et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed Non-Hodgkin's lymphoma. *Jour. of Clinic. Oncol.*, 1997.10, Vol. 15, No. 10, s. 3266-74, ()

MCLAUGHLIN, P. et al. Rituximab chimeric anti-CD20 monoklonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. 1998.08, Vol. 16, No. 8, s. 2825-33, ()

VAN DER KOLK, L.E. et al. Chimeric anti-CD20 monoklonal antibody (Rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial, 1998.07.01, *Brit. Jour. of haematol.*, Vol. 102, No. 1. ()

ARRANZ REYES, ET AL., Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. *Jour. Clin. Oncol.* April 1998; Vol. 16(4), s. 1538-46. ()

Hochster, H. S. ET AL., Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. *Blood (ASH Annual Meeting Abstracts)*, 2005, 106: Abstract 349. ()

## Administrative review

NIPO's case no. 2017/00085  
Filed 2017.02.27  
Current status 2017.04.03 Performed

### Claimant

OSLO PATENTKONTOR AS  
Hoffsveien 1A  
0275 OSLO  
NO ( OSLO Municipality, OSLO county )

Org. number: 910476068

### Claimant's agent

OSLO PATENTKONTOR AS  
Hoffsveien 1A  
0275 OSLO  
NO ( OSLO Municipality, OSLO county )

Org. number: 910476068

## Status history for 2017/00085

Legal status	Decision date, detailed status
2017.04.03 Performed	2017.04.03 The right has been changed as a result of administrative review or patent limitation
2017.02.27 Pending	2017.04.03 Letter with due date issued
2017.02.27 Pending	2017.03.07 Letter with due date issued
2017.02.27 Pending	2017.02.28 Received

## Correspondence for 2017/00085

Date	Correspondence type	Journal description
2017.04.03	Outgoing	OP10: Oversendelsesbrev med avgjørelse uten klagefrist
2017.03.09	Incoming, AR186070508	Korrespondanse (Hovedbrev inn)
2017.03.07	Outgoing	Mangelbrev

---

2017.03.01	Incoming, AR185167762	Korrespondanse (Hovedbrev inn)
2017.02.27	Incoming, AR184889052	Nytt overprøvningskrav (OP)

---

Information about documents which are not available

## Case history

### Status history

Legal status	Decision date, detailed status
2019.08.11 Ceased	2019.09.03 Patent protection period expired
2013.01.28 Granted	2017.04.03 Granted (B3) with changes after administrative overruling or administrative reevaluation
2013.01.28 Granted	2016.12.22 Message about invalidation case or transfer of patent case for court has been received.
2013.01.28 Granted	2013.01.21 Granted (B1)
2001.02.09 Pending	2012.11.01 Accepted for grant
2001.02.09 Pending	2012.07.04 Second and later letter exists
2001.02.09 Pending	2012.03.22 Second and later letter exists
2001.02.09 Pending	2011.10.13 Second and later letter exists
2001.02.09 Pending	2011.04.06 Second and later letter exists
2001.02.09 Pending	2010.12.23 Case handling is resumed
2010.09.09 Shelved	2010.09.16 Not answered in due time (PL § 15)
2001.02.09 Pending	2010.05.07 Second and later letter exists
2001.02.09 Pending	2009.04.01 First letter of examination exists
2001.02.09 Pending	2001.02.09 New application created

### Correspondence

Date	Correspondence type	Journal description
2019.09.03	Outgoing	PT Utløpt 20 år (3315)
2017.09.07	Incoming, AR184889052	Krav
2017.01.06	Outgoing	Bekreftelse mottatt melding om søksmål
2017.01.06	Incoming	Melding om søksmål
2013.01.30	Outgoing	PT Registreringsbrev Nasjonal Patent
2012.11.05	Outgoing	PT Meddelelse om patent
2012.08.30	Incoming	Korrespondanse (hoved dok)
2012.07.04	Outgoing	Realitet patent

2012.05.10	Incoming	Korrespondanse (hoved dok)
2012.03.22	Outgoing	Realitet patent
2012.01.11	Incoming	Korrespondanse (hoved dok)
2011.10.13	Outgoing	Realitet patent
2011.07.07	Incoming	Korrespondanse (hoved dok)
2011.04.06	Outgoing	Realitet patent
2010.11.10	Incoming	Korrespondanse (hoved dok)
2010.09.20	Outgoing	Henlagt manglende svar
2010.09.20	Outgoing	Henlagt manglende svar
2010.05.07	Outgoing	Realitet patent
2010.02.05	Incoming	Korrespondanse (hoved dok)
2009.12.04	Incoming	Korrespondanse (hoved dok)
2009.10.02	Incoming	Korrespondanse (hoved dok)
2009.04.01	Outgoing	PT Realitet_patent (2009.04.01)

Information about documents which are not available



## Payment

Payment due:

Payment history:

Description / Invoice number	Payment date	Amount	Payer	Status
Annual fee 20th year	2018.07.26	6500	MASTER DATA INC	Paid and approved
Annual fee 19th year	2017.07.26	6200	MASTER DATA INC	Paid and approved
Annual fee 18th year	2016.07.25	5800	MASTER DATA INC	Paid and approved
Annual fee 17th year	2015.07.27	5500	Master Data Center Inc	Paid and approved
Annual fee 16th year	2014.07.25	5200	Master Data Center Inc	Paid and approved
Annual fee 15th year	2013.07.26	4400	Master Data Center Inc	Paid and approved
31213747	2012.11.09	7100	Oslo Patentkontor AS	Paid
Annual fee 14th year	2012.08.09	4100	Computer Patent Annuities Ltd	Paid and approved
Annual fee 13th year	2011.07.20	3800	Computer Packages Inc	Paid and approved
31013977	2010.12.07	900	Oslo Patentkontor AS	Paid
Annual fee 12th year	2010.07.21	2850	Computer Packages Inc	Paid and approved
Annual fee 11th year	2009.07.21	2850	Computer Packages Inc	
Annual fee 10th year	2008.07.21	2850	Computer Packages Inc	
Annual fee 9th year	2007.07.19	1900	Computer Packages Inc	
Annual fee 8th year	2006.07.19	1900	Computer Packages Inc	

Annual fee 7th year	2005.07.21	1900	Computer Packages Inc
Annual fee 6th year	2004.08.11	1000	Computer Patent Annuities Ltd
		0	
		0	
		0	

This economic overview may lack information, particularly for older cases, for reimbursements, international trademarks and international designs.

### Publication(s)

Links to publications and the Norwegian Patent Gazette (searchable text documents)

Last published version of the patent

Link to the Norwegian Patents Gazette - when granted

Links to publications (only image files)

B3

B1

A

What does A1, B, B1, C stand for?

Chapters without data are removed.

Document created: 13.05.2021 15:14:03

>